<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666883</url>
  </required_header>
  <id_info>
    <org_study_id>REGISTROSPERIMENTAZIONI/21</org_study_id>
    <nct_id>NCT04666883</nct_id>
  </id_info>
  <brief_title>Splenic Hilar Nodes in Splenic Flexure Cancer</brief_title>
  <official_title>Aberrant Lympahtic Drainage of Splenic Flexure Cancer: Are Splenic Hilar Nodes Metastases an Underecognized Phenomenon?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rome Tor Vergata</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Rome Tor Vergata</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Report the incidence of metastases to the splenic hilar lymphnodes from splenic flexure&#xD;
      primaries. This mode of spread has not been previously characterized for these tumours.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Splenic hilum nodal metastases</measure>
    <time_frame>5 years</time_frame>
    <description>Splenic hilum nodal metastases</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Metastases, Lymphatic</condition>
  <arm_group>
    <arm_group_label>Splenic flexure cancer patients</arm_group_label>
    <description>Splenic flexure cancer patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Review of records and follow up</intervention_name>
    <description>Follow up to identify patients who developed splenic hilar nodal metastases</description>
    <arm_group_label>Splenic flexure cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with cancer of the splenic flexure of the colon&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All splenic flexure cancer patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No consent to data utilization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bruno Sensi, MD</last_name>
    <phone>3385352902</phone>
    <email>brunosensi@outlook.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Giuseppe S Sica, MD, PhD</last_name>
    <phone>3385333659</phone>
    <email>sigisica@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Bruno Sensi, MD</last_name>
      <phone>+39 3385352902</phone>
      <email>brunosensi@outlook.it</email>
    </contact>
    <contact_backup>
      <last_name>Giuseppe S Sica, MD, PhD</last_name>
      <phone>+39 3385333659</phone>
      <email>sigisica@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>December 24, 2020</last_update_submitted>
  <last_update_submitted_qc>December 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rome Tor Vergata</investigator_affiliation>
    <investigator_full_name>Giuseppe Sigismondo Sica</investigator_full_name>
    <investigator_title>Associate Professor, Head of Department</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

